Could your own tumor cells fight cancer? new trial tests immune cell therapy
NCT ID NCT01174121
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, or neuroendocrine cancers. Participants first undergo surgery to remove a tumor for cell production, then receive chemotherapy to prepare their body, followed by the cell infusion and pembrolizumab. The study aims to see if this combination is safe and effective for cancers that have not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tumor-infiltrating lymphocytes (TIL) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could offer a new treatment option for several hard-to-treat metastatic cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to all patients. The treatment involves intensive chemotherapy and hospital stays, and may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States